Ethical considerations in determining standard of prevention packages for HIV prevention trials: Examining PrEP

Bridget Haire, Morenike Oluwatoyin Folayan, Catherine Hankins, Jeremy Sugarman, Sheena Mccormack, Gita Ramjee, Mitchell Warren

Research output: Contribution to journalArticle

Abstract

The successful demonstration that antiretroviral (ARV) drugs can be used in diverse ways to reduce HIV acquisition or transmission risks - either taken as pre-exposure prophylaxis (PrEP) by those who are uninfected or as early treatment for prevention (T4P) by those living with HIV - expands the armamentarium of existing HIV prevention tools. These findings have implications for the design of future HIV prevention research trials. With the advent of multiple effective HIV prevention tools, discussions about the ethics and the feasibility of future HIV prevention trial designs have intensified. This article outlines arguments concerning the inclusion of newly established ARV-based HIV prevention interventions as standard of prevention in HIV prevention trials from multiple perspectives. Ultimately, there is a clear need to incorporate stakeholders in a robust discussion to determine the appropriate trial design for each study population.

Original languageEnglish (US)
Pages (from-to)87-94
Number of pages8
JournalDeveloping World Bioethics
Volume13
Issue number2
DOIs
StatePublished - Aug 2013

Keywords

  • Antiretroviral therapy
  • Developing world bioethics
  • Guidelines
  • HIV/AIDS
  • International justice
  • Research ethics

ASJC Scopus subject areas

  • Issues, ethics and legal aspects
  • Health(social science)
  • Health Policy

Fingerprint Dive into the research topics of 'Ethical considerations in determining standard of prevention packages for HIV prevention trials: Examining PrEP'. Together they form a unique fingerprint.

  • Cite this